Genelux (GNLX) Expected to Release Quarterly Earnings on Wednesday

Genelux (NASDAQ:GNLX) will likely be posting its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Genelux to announce earnings of ($0.20) per share for the quarter. Investors can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Genelux (NASDAQ:GNLX) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). On average, analysts expect Genelux to post ($0.81) EPS for the current fiscal year and ($0.68) EPS for the next fiscal year.

Genelux Trading Down 3.8%

Shares of GNLX stock opened at $2.00 on Tuesday. The firm has a 50-day moving average price of $2.45 and a 200 day moving average price of $2.69. Genelux has a twelve month low of $1.86 and a twelve month high of $8.53. The company has a market capitalization of $90.48 million, a price-to-earnings ratio of -2.33 and a beta of 0.59.

Analyst Upgrades and Downgrades

Several research firms have issued reports on GNLX. Wall Street Zen raised shares of Genelux from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 20th. Benchmark reiterated a “speculative buy” rating on shares of Genelux in a report on Tuesday, August 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Genelux in a research report on Thursday, October 15th. Finally, Lucid Cap Mkts raised shares of Genelux to a “strong-buy” rating in a research note on Wednesday, September 16th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $20.00.

Insider Buying and Selling at Genelux

In related news, CEO Thomas Zindrick sold 34,463 shares of the company’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $2.67, for a total value of $92,016.21. Following the completion of the transaction, the chief executive officer directly owned 1,226,427 shares in the company, valued at approximately $3,274,560.09. This represents a 2.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Yong Yu sold 9,683 shares of the company’s stock in a transaction on Monday, August 31st. The shares were sold at an average price of $2.75, for a total value of $26,628.25. Following the completion of the transaction, the insider owned 258,688 shares of the company’s stock, valued at $711,392. The trade was a 3.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 7.50% of the stock is owned by company insiders.

About Genelux

Genelux Corporation is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer. The company’s lead product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, genetically modified oncolytic vaccinia virus designed to selectively infect and destroy tumor cells while stimulating an immune response against cancer.

Genelux is evaluating Olvi-Vec in combination with other treatments across multiple solid-tumor indications. Its clinical development efforts have included ovarian cancer, where the candidate is being studied in patients with advanced or recurrent disease, as well as other potential applications in cancers such as colorectal and lung cancer.

Founded in 2001 and headquartered in San Diego, California, Genelux conducts its research and clinical development activities primarily in the United States.